Advantages of modified drug delivery system in psychiatry

Anant D. Patil

Abstract


Non-compliance is a common problem in chronic diseases including psychiatric disorders. Various attempts have been made for improving adherence in psychiatry; one of them being simplifying dosage regimen by designing modified dosage formulation. For example, depot formulation, oral disintegrating tablets or extended release formulations are some of the strategies for improving compliance in psychiatry patients. Modified dosage formulations also have some other advantages too. For example, oral disintegrating tablet of olanzapine cause lesser weight gain compared to standard olanzapine tablet while Zolpidem extended release tablet provides better sleep maintenance in middle of night. This article reviews some of the modified dosage formulations in psychiatric diseases with their advantages.


Keywords


Psychiatry, Dosage form, Compliance, Advantages

Full Text:

PDF

References


Magura S, Rosenblum A, Fong C. Factors associated with medication adherence among psychiatric outpatients at substance abuse risk. The Open Addiction Journal 2011;4:58-64.

Seltzer A and Hoffman BF. Drug compliance of the psychiatric patient. Can Fam Physician 1980;26: 725-7.

Bener A, Dafeeah EF, Salem MO. A study of reasons of non-compliance of psychiatric treatment and patients’ attitudes towards illness and treatment in Qatar. Issues in Mental Health Nursing. April 2013;34:273-80.

Stoner SC, Dahmen MM. Extended-release divalproex in bipolar and other psychiatric disorders: Acomprehensive review. Neuropsychiatric Disease and Treatment 2007;3(6):839-46.

Montgomery W, Treuer T, Karagianis J, Ascher-Svanum H, Harrison G. Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties. Patient Preference and Adherence 2012;6:109-25.

Shukla RK, Sarkar P, Mishra A. Weight loss after switching to olanzapine mouth dissolving tablets-An open label prospective study. Orissa Journal Psychiatry 2009;27-30.

Gahr M, Kölle MA, Schönfeldt-Lecuona C, Lepping P, Freudenmann RW. Paliperidone extended-release: does it have a place in antipsychotic therapy? Drug Design, Development and Therapy 2011;5:125-46.

Rainer MK. Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsychiatric Disease and Treatment 2008;4(5):919-27.

Balaraman R, Gandhi H. Asenapine, a new sublingual atypical antipsychotic. J Pharmacol Pharmacother 2010;1(1):60-1.

Citrome L. Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat 2011;7:325-39.

Moen MD, Plosker GL. Zolpidem extended release. CNS Drugs 2006;20(5):419-26.

Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T. Long-Term Efficacy and Safety of Zolpidem Extended-Release 12.5 mg, Administered 3 to 7 Nights Per Week for 24 Weeks, in Patients With Chronic Primary Insomnia: A 6-Month, Randomized, Double- Blind, Placebo-Controlled, Parallel-Group, Multicenter Study. Sleep 2008;31:79-90.